European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME: Berlin Saturday, June 28, 2025, 09:00 Hrs [IST] The Eur ...

The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025 and is projected to advance at ...

Biocon said that its subsidiary Biocon Biologics has received a notice of compliance (NOC) for Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, in vial and prefilled syringe ...

Notably, every major breakthrough medication for retinal diseases—including ranibizumab, aflibercept, faricimab, brolucizumab ...

Indian drugmaker Biocon has announced that Health Canada has granted a Notice of Compliance for Yesafili (aflibercept), a ...

Biocon Biologics receives Health Canada approval for Yesafili, the first Eylea biosimilar in Canada, with launch slated for ...

TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BS ...

Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME.

The Supervisory Board of AS Harju Elekter Group decided to increase the share capital of the company by 17,010 euros by issuing new ordinary shares. The increase in the share capital is due to the ...

Bengaluru: Biocon Biologics Ltd ., a fully integrated global biosimilars company and a subsidiary of Biocon Ltd ., has ...

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch ...